O	0	8	Baseline
O	9	16	Factors
O	17	26	Affecting
O	27	34	Changes
O	35	37	in
B-Classification_system	38	46	Diabetic
I-Classification_system	47	58	Retinopathy
I-Classification_system	59	67	Severity
I-Classification_system	68	73	Scale
I-Classification_system	74	79	Score
O	80	85	After
O	86	98	Intravitreal
O	99	110	Aflibercept
O	111	113	or
O	114	119	Laser
O	120	123	for
B-Disease	124	132	Diabetic
I-Disease	133	140	Macular
I-Disease	141	146	Edema
O	146	147	:
O	148	152	Post
O	153	156	Hoc
O	157	165	Analyses
O	166	170	from
O	171	176	VISTA
O	177	180	and
O	181	186	VIVID
O	186	187	.

O	189	191	To
O	192	200	evaluate
O	201	208	whether
O	209	215	select
O	216	224	baseline
O	225	233	systemic
O	234	237	and
O	238	244	ocular
O	245	252	factors
O	253	262	influence
B-Classification_system	263	264	≥
I-Classification_system	264	265	2
I-Classification_system	265	266	-
I-Classification_system	266	270	step
I-Classification_system	271	282	improvement
I-Classification_system	283	285	in
I-Classification_system	286	289	the
I-Classification_system	290	298	Diabetic
I-Classification_system	299	310	Retinopathy
I-Classification_system	311	319	Severity
I-Classification_system	320	325	Scale
I-Classification_system	326	327	(
I-Classification_system	327	331	DRSS
I-Classification_system	331	332	)
I-Classification_system	333	338	score
O	339	341	at
O	342	346	week
O	347	350	100
O	351	353	in
O	354	359	VISTA
O	360	363	and
O	364	369	VIVID
O	369	370	.

O	371	375	Post
O	376	379	hoc
O	380	388	analysis
O	389	391	of
O	392	393	2
O	394	403	similarly
O	404	412	designed
O	413	418	phase
O	419	420	3
O	421	427	trials
O	427	428	,
O	429	434	VISTA
O	435	438	and
O	439	444	VIVID
O	444	445	.

O	446	451	Total
O	452	454	of
O	455	458	456
O	459	467	patients
O	468	472	with
O	473	479	center
O	479	480	-
O	480	488	involved
B-Disease	489	497	diabetic
I-Disease	498	505	macular
I-Disease	506	511	edema
O	512	513	(
B-Disease	513	516	DME
O	516	517	)
O	517	518	.

O	519	524	VISTA
O	525	528	and
O	529	534	VIVID
O	535	545	randomized
O	546	549	872
B-Disease	550	553	DME
O	554	562	patients
O	563	565	to
O	566	573	receive
O	574	586	intravitreal
O	587	598	aflibercept
O	599	608	injection
O	609	610	(
O	610	613	IAI
O	613	614	)
O	615	616	2
O	617	619	mg
O	620	625	every
O	626	627	4
O	628	633	weeks
O	634	635	(
O	635	638	2q4
O	638	639	)
O	639	640	,
O	641	644	IAI
O	645	646	2
O	647	649	mg
O	650	655	every
O	656	657	8
O	658	663	weeks
O	664	669	after
O	670	671	5
O	672	679	monthly
O	680	685	doses
O	686	687	(
O	687	690	2q8
O	690	691	)
O	691	692	,
O	693	695	or
O	696	703	macular
O	704	709	laser
O	710	726	photocoagulation
O	726	727	.

O	728	732	This
O	733	737	post
O	738	741	hoc
O	742	750	analysis
O	751	760	evaluated
O	761	764	the
O	765	774	influence
O	775	777	of
O	778	784	select
O	785	793	baseline
O	794	801	factors
O	802	804	on
B-Classification_system	805	806	≥
I-Classification_system	806	807	2
I-Classification_system	807	808	-
I-Classification_system	808	812	step
I-Classification_system	813	817	DRSS
I-Classification_system	818	823	score
O	824	835	improvement
O	836	838	by
O	839	847	logistic
O	848	858	regression
O	859	861	in
O	862	864	an
O	865	875	integrated
O	876	881	VISTA
O	882	885	and
O	886	891	VIVID
O	892	899	dataset
O	900	905	using
O	906	914	observed
O	915	920	cases
O	921	922	(
O	922	923	n
O	924	925	=
O	926	929	456
O	929	930	)
O	931	935	with
O	936	944	patients
O	945	947	in
O	948	952	each
O	953	962	treatment
O	963	968	group
O	969	976	divided
O	977	981	into
O	982	990	tertiles
O	991	996	based
O	997	999	on
O	1000	1004	each
O	1005	1019	characteristic
O	1019	1020	.

O	1021	1031	Proportion
O	1032	1034	of
O	1035	1043	patients
O	1044	1048	with
B-Classification_system	1049	1050	≥
I-Classification_system	1050	1051	2
I-Classification_system	1051	1052	-
I-Classification_system	1052	1056	step
I-Classification_system	1057	1068	improvement
I-Classification_system	1069	1071	in
I-Classification_system	1072	1076	DRSS
I-Classification_system	1077	1082	score
O	1083	1087	from
O	1088	1096	baseline
O	1097	1099	at
O	1100	1104	week
O	1105	1108	100
O	1109	1111	by
B-Characteristic	1112	1115	age
O	1115	1116	,
B-Characteristic	1117	1125	duration
I-Characteristic	1126	1128	of
I-Characteristic	1129	1137	diabetes
O	1137	1138	,
B-Characteristic	1139	1149	hemoglobin
I-Characteristic	1150	1153	A1c
O	1154	1155	(
B-Characteristic	1155	1160	HbA1c
O	1160	1161	)
O	1161	1162	,
B-Characteristic	1163	1167	body
I-Characteristic	1168	1172	mass
I-Characteristic	1173	1178	index
O	1179	1180	(
B-Characteristic	1180	1183	BMI
O	1183	1184	)
O	1184	1185	,
B-Characteristic	1186	1190	best
I-Characteristic	1190	1191	-
I-Characteristic	1191	1200	corrected
I-Characteristic	1201	1207	visual
I-Characteristic	1208	1214	acuity
O	1215	1216	(
B-Characteristic	1216	1220	BCVA
O	1220	1221	)
O	1221	1222	,
B-Characteristic	1223	1230	central
I-Characteristic	1231	1239	subfield
I-Characteristic	1240	1249	thickness
O	1250	1251	(
B-Characteristic	1251	1254	CST
O	1254	1255	)
O	1255	1256	,
O	1257	1260	and
B-Classification_system	1261	1265	DRSS
I-Classification_system	1266	1271	score
O	1271	1272	.

O	1273	1275	At
O	1276	1280	week
O	1281	1284	100
O	1284	1285	,
O	1286	1288	10
O	1288	1289	.
O	1289	1290	1
O	1290	1291	%
O	1291	1292	,
O	1293	1295	34
O	1295	1296	.
O	1296	1297	3
O	1297	1298	%
O	1298	1299	,
O	1300	1303	and
O	1304	1306	37
O	1306	1307	.
O	1307	1308	6
O	1308	1309	%
O	1310	1312	of
O	1313	1321	patients
O	1322	1324	in
O	1325	1328	the
O	1329	1334	laser
O	1334	1335	,
O	1336	1339	2q4
O	1339	1340	,
O	1341	1344	and
O	1345	1348	2q8
O	1349	1355	groups
O	1356	1367	experienced
O	1368	1369	a
B-Classification_system	1370	1371	≥
I-Classification_system	1371	1372	2
I-Classification_system	1372	1373	-
I-Classification_system	1373	1377	step
I-Classification_system	1378	1382	DRSS
I-Classification_system	1383	1388	score
O	1389	1400	improvement
O	1400	1401	,
O	1402	1414	respectively
O	1414	1415	.

B-Characteristic	1416	1419	Age
O	1419	1420	,
B-Characteristic	1421	1429	duration
I-Characteristic	1430	1432	of
I-Characteristic	1433	1441	diabetes
O	1441	1442	,
B-Characteristic	1443	1448	HbA1c
O	1448	1449	,
B-Characteristic	1450	1453	BMI
O	1453	1454	,
B-Characteristic	1455	1459	BCVA
O	1459	1460	,
O	1461	1464	and
B-Characteristic	1465	1468	CST
O	1469	1472	had
O	1473	1475	no
O	1476	1482	impact
O	1483	1485	on
O	1486	1489	the
O	1490	1497	ability
O	1498	1500	to
O	1501	1508	achieve
O	1509	1510	≥
O	1510	1511	2
O	1511	1512	-
O	1512	1516	step
O	1517	1528	improvement
O	1529	1531	in
B-Classification_system	1532	1536	DRSS
I-Classification_system	1537	1542	score
O	1542	1543	.

O	1544	1551	Initial
B-Classification_system	1552	1556	DRSS
I-Classification_system	1557	1562	score
O	1563	1566	was
O	1567	1570	the
O	1571	1575	only
O	1576	1582	factor
O	1583	1596	significantly
O	1597	1607	associated
O	1608	1612	with
B-Classification_system	1613	1614	≥
I-Classification_system	1614	1615	2
I-Classification_system	1615	1616	-
I-Classification_system	1616	1620	step
I-Classification_system	1621	1625	DRSS
I-Classification_system	1626	1631	score
O	1632	1643	improvement
O	1644	1646	in
O	1647	1650	all
O	1651	1660	treatment
O	1661	1667	groups
O	1668	1670	at
O	1671	1676	weeks
O	1677	1679	24
O	1679	1680	,
O	1681	1683	52
O	1683	1684	,
O	1685	1687	76
O	1687	1688	,
O	1689	1692	and
O	1693	1696	100
O	1696	1697	.

O	1698	1708	Relatively
O	1709	1715	higher
O	1716	1727	proportions
O	1728	1730	of
O	1731	1734	IAI
O	1734	1735	-
O	1735	1742	treated
O	1743	1751	patients
O	1752	1756	with
O	1757	1762	worse
B-Characteristic	1763	1767	BCVA
O	1768	1770	or
O	1771	1778	thicker
B-Characteristic	1779	1782	CST
O	1783	1794	experienced
B-Classification_system	1795	1796	≥
I-Classification_system	1796	1797	2
I-Classification_system	1797	1798	-
I-Classification_system	1798	1802	step
I-Classification_system	1803	1807	DRSS
I-Classification_system	1808	1813	score
O	1814	1825	improvement
O	1826	1834	compared
O	1835	1839	with
O	1840	1845	those
O	1846	1850	with
O	1851	1857	better
B-Characteristic	1858	1862	BCVA
O	1863	1865	or
O	1866	1873	thinner
B-Characteristic	1874	1877	CST
O	1877	1878	,
O	1879	1891	respectively
O	1891	1892	,
O	1893	1896	but
O	1897	1902	these
O	1903	1915	associations
O	1916	1920	were
O	1921	1924	not
O	1925	1938	statistically
O	1939	1950	significant
O	1950	1951	.

O	1952	1953	A
O	1954	1960	strong
O	1961	1972	association
O	1973	1976	was
O	1977	1984	present
O	1985	1992	between
B-Classification_system	1993	2001	baseline
I-Classification_system	2002	2006	DRSS
I-Classification_system	2007	2012	score
O	2013	2016	and
B-Classification_system	2017	2018	≥
I-Classification_system	2018	2019	2
I-Classification_system	2019	2020	-
I-Classification_system	2020	2024	step
I-Classification_system	2025	2029	DRSS
I-Classification_system	2030	2035	score
O	2036	2047	improvement
O	2048	2050	at
O	2051	2055	week
O	2056	2059	100
O	2060	2063	for
B-Disease	2064	2067	DME
O	2068	2076	patients
O	2077	2079	in
O	2080	2085	VISTA
O	2086	2089	and
O	2090	2095	VIVID
O	2095	2096	.
